Apocrine carcinoma of the breast: the decisions you may face

Cancer page →Second-opinion finder →

1 treatment setting, 1 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.

Other settings

Triple-negative apocrine carcinoma

2 optionsCompare side by side →

As for triple-negative disease of no special type; androgen receptor antagonists only within trials (clinical benefit rates 19 to 33 percent in phase 2).

The options, in plain words

BicalutamideApprovedOral first-generation non-steroidal antiandrogen

The old antiandrogen pill used to block the testosterone flare from GnRH agonists and in combined androgen blockade; superseded by enzalutamide-class drugs.

EnzalutamideApprovedSmall-molecule AR antagonist

Enzalutamide is a second-generation androgen-receptor blocker that stops the receptor binding testosterone, entering the nucleus and switching on genes. It is approved at every stage of advanced prostate cancer, from rising PSA after surgery to castration-resistant disease, and fatigue, falls and memory problems are its main drawbacks.

Also referenced:Androgen receptor

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record

Enzalutamide all recorded rates →

Seizure risk: caution with drugs that lower the seizure threshold.

Questions to ask about this decision

Between Bicalutamide and Enzalutamide, which do you recommend for me, and what about my case would make you choose differently?
Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
For my situation (triple-negative apocrine carcinoma), which of the standard options do you recommend and why?
Why: Guideline options include: As for triple-negative disease of no special type; androgen receptor antagonists only within trials (clinical benefit rates 19 to 33 percent in phase 2).
Am I a candidate for Bicalutamide, Enzalutamide, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.

Add these to your appointment list, or take the full question set for this cancer.

How to read this page. Options and results come from OnCo records with their sources; the settings are the standard-of-care rows on the cancer page, and the lines of therapy are on the sequencing grid. Where a setting names one path, the choice is usually about timing, trials and where to be treated: see expert centres. OnCo is orientation, not medical advice.

Living with cancer·Standard of care